ID
16688
Beskrivning
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Study Drug Administration
Länk
https://clinicaltrials.gov/ct2/show/NCT00373425
Nyckelord
Versioner (2)
- 2016-07-27 2016-07-27 -
- 2016-08-01 2016-08-01 -
Uppladdad den
1 augusti 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Similar models
Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C3840932 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,2])